Please ensure Javascript is enabled for purposes of website accessibility

Is Amazon a Buy?

By Zhiyuan Sun - Updated Mar 19, 2021 at 9:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The nation's No. 1 e-commerce giant is now seeking to disrupt the healthcare sector.

Now worth more than $3,000 a share, Amazon (AMZN 0.25%) has been one of the top-performing growth stocks of the past year, with a close to 70% return. From its signature sales platform to Kindle Publishing to Amazon Fresh grocery delivery to Amazon Music to Prime Video to Alexa, it has developed several magnificent innovations in the past two decades.

But its momentum is far from over; Amazon will soon become part of the $4 trillion U.S. healthcare industry. Should you buy the stock as a bet on its new venture? 

Pharmacists checking shipments in a warehouse.

Image source: Getty Images.

What's the big deal?

Through Amazon Pharmacy, the company is now offering its Prime members in 45 states free two-day shipping and delivery for all their prescription drug needs. Over 50,000 pharmacies across the nation are on board with Amazon's new venture. If patients do not have insurance, they can enjoy up to 80% savings on generic drugs and 40% savings on branded drugs if they purchase their medication through Amazon.

What's more, the e-commerce giant is also launching Amazon Care to provide telehealth services to its employees nationwide. These include consultations for treating illness/injury, COVID-19 testing, flu shots, nutrition and diet consultations, and pregnancy planning. The company did an 18-month trial of the service in its Washington office and saw spectacular success. It is planning to expand Amazon Care to other employers as well, and perhaps even to its members.

The great thing about Amazon's new initiative is that there exists a significant overlap between Amazon Care and Amazon Pharmacy. If the former becomes available to Prime members, patients could seek a consultation via Amazon Care and have their prescriptions filled directly through Amazon Pharmacy, creating ample revenue synergies. 

The telehealth and prescription drug industry amounts to $774 billion in the U.S. alone. Amazon's potential market outreach is far more extensive than this, as it could easily scale both segments on an international level. 

It has also been doing well outside of healthcare. Last year, the company's revenue increased by 38% year over year to $386.1 billion. Simultaneously, Amazon's free cash flow increased to $31 billion from $25.8 billion in the prior year. Over the holiday season, the company delivered more than 1 billion toys, home decorations, clothing items, electronics, beauty products, and personal care items worldwide. The sky is truly the limit in terms of what Amazon has to offer. 

Is the stock a buy?

Usually, investors are skeptical of blue-chip stocks that reach $100 billion annually. After this feat, it can be extremely difficult for companies to expand outside of their principal business scope. That's simply not the case for Amazon, which has proven that its e-commerce model is scalable to just about any kind of service, putting the company on a path to becoming a multinational conglomerate. 

At a time when the average e-commerce stock trades for 4.52 times revenue, Amazon's 3.23 times sales valuation is an absolute bargain. I'd highly recommend those who are enthusiastic about retail or healthcare stocks to add the company to their watch list. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amazon.com, Inc. Stock Quote
Amazon.com, Inc.
AMZN
$2,151.82 (0.25%) $5.44

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.